Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Viatris Inc
VTRS
Healthcare
Biotechnology
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The...
Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:VTRS)
New Post
View:
Posts & Comments
Threaded Posts
(10)
•••
MikeTester
X
Post by
MikeTester
on Aug 02, 2024 10:08am
Viatris Inc. (NASDAQ:VTRS) – Bridging the Divide Betwe
https://beyondspx.com/2024/08/01/viatris-inc-nasdaqvtrs-bridging-the-divide-between-generics-and-brands/
(1748)
•••
Possibleidiot01
X
Post by
Possibleidiot01
on Mar 14, 2023 6:38am
Lorne Steinberg still lilkes - BNN
TOP PICK Viatris(VTRS-Q) 13/03/2023 It is the cheapest stock in their portfolio at 4X earnings, a pharma company formed by a joint venture. Its
...more
(3)
•••
jonahg
X
Post by
jonahg
on Aug 03, 2022 10:18am
Though a small drug-maker...
with a market capitalization of just under $14 billion, this pharmaceutical company is worth a look thanks to its consistent and generous dividend payments.
(13)
•••
Cdnmate23
X
Comment by
Cdnmate23
on Feb 03, 2022 2:01pm
RE:Paul MacDonALD- BNN - Don't BUY
Lorne and Paul need to go out for a coffee and discuss further. I have no issue holding and not worrying about this one for many years, at some point its valuation will attract cyclical value
...more
(1748)
•••
Possibleidiot01
X
Post by
Possibleidiot01
on Feb 03, 2022 1:55pm
Paul MacDonALD- BNN - Don't BUY
DON'T BUY Viatris(VTRS-Q) 02/02/2022 at 07:00pm Includes boring drugs, which provide consistent cashflows. Bit of growth in its biosimilar business, but talk
...more
(1748)
•••
Possibleidiot01
X
Comment by
Possibleidiot01
on Dec 22, 2021 4:19pm
RE:RE:Lorne Steinberg on BNN - BUY
Still banging the drum for the stock. PAST TOP PICK Viatris(VTRS-Q) (A Top Pick Dec 22/20, Down 24%) By far the cheapest cost
...more
(1748)
•••
Possibleidiot01
X
Comment by
Possibleidiot01
on Nov 11, 2021 2:18pm
RE:Lorne Steinberg on BNN - BUY
STRONG BUY Viatris(VTRS-Q) PE is around 5. Cheapest stock in his portfolio. First quarter, they underdelivered and the stock was punished. Last quarter, management delivered.
...more
(1748)
•••
Possibleidiot01
X
Post by
Possibleidiot01
on Jun 28, 2021 8:18pm
Lorne Steinberg on BNN - BUY
Viatris (VTRS-Q) June 28, 2021 It is the cheapest stock he owns. They came to market and disappointed with their first quarter. The are being punished by the street. They are now a
...more
(0)
•••
lizsell
X
Post by
lizsell
on Mar 04, 2021 12:25pm
Viatris Posion
Rajiv Malik president up for price fixing, Chairmen Robert Coury Epipen scandal and drew attiontion for FDA for bad practices and blamed it all on former CEO heather Bresch. Pfizer made a deal
...more
(0)
•••
lizsell
X
Comment by
lizsell
on Mar 04, 2021 12:21pm
RE:RE:More info....COMMENTS
Wrong they lowered that est. and will also put options for apr. 23rd a desperate move for a company around only 3 months. They are in trouble already, but with Robert Coury at the helm you could
...more
(4)
•••
Aminvestor1234
X
Comment by
Aminvestor1234
on Jan 25, 2021 10:28pm
RE:More info....COMMENTS
Newly formed company. Very little data or history to speak of. Looks interesting.
(91)
•••
Podios2
X
Comment by
Podios2
on Jan 05, 2021 5:35am
RE:More info....COMMENTS
I heard this company will paying a 5% div soon?
(6)
•••
nolalu
X
Post by
nolalu
on Dec 25, 2020 1:14pm
More info....COMMENTS
Anyone comment on this company.? https://stockchase.com/company/view/6587/VTRS-Q
(6)
•••
nolalu
X
Post by
nolalu
on Dec 24, 2020 3:13pm
Looks very interesting and div. coming soon.
Title says it all....
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Largest integrated facility services provider in Canada releases financial results for Q1, 2025
This company is set to benefit from a change in Ontario legislation
How Web3 Will Fundamentally Reshape Finance